SEDAR Interim Financial Statements

Page | 1 Condensed Consolidated Interim Financial Statements (Stated in Canadian Dollars) For the three months and nine months ended September 30, 2025 Leveljump Healthcare Corp. Condensed Consolidated Interim statement of ?nancial position at September 30, 2025 Stated in Canadian dollars Page | 2 Notes 30-Sep-25 31-Dec-24 Assets Current assets Cash 111,508 $ 52,600 $ Accounts receivable 1,229,908 1,400,285 HST receivable - 61,551 Prepaid expenses and deposits 151,364 138,592 Due from related parties 12 1,820,232 1,567,078 3,313,011 $ 3,220,105 $ Non-current assets Property, plant and equipment 4,184,206 4,439,589 Intangible assets and goodwill 9,909,653 9,883,193 Right-of-use assets 8 2,161,202 1,414,201 Deferred tax asset 2,267,991 2,267,991 18,523,052 $ 18,004,974 $ Total assets 21,836,063 $ 21,225,080 $ Equity and liabilities Current liabilities Accounts payable and accrued liabilities 3,751,025 $ 3,530,067 $ Operating line of credit 7(b) 655,309 642,288 Lease liabilities current portion 8 554,972 1,079,707 Loans current portion 7(b) 980,218 935,249 5,941,524 $ 6,187,311 $ Non-current liabilities Loans non current portion 7(b) 5,376,335 5,892,649 Preferred shares liability 2,471,896 2,159,922 Lease liabilities non current portion 8 1,697,548 402,615 Statute barred liabilities - 222,327 9,545,780 $ 8,677,513 $ Total liabilities 15,487,304 $ 14,864,824 $ Equity Share capital 10 16,230,025 16,230,025 Contributed surplus 5,552,263 5,552,263 Equity component of preferred shares 87,859 105,109 Deficit (15,521,387) (15,527,141) Total equity 6,348,759 $ 6,360,256 $ Total equity and liabilities 21,836,063 $ 21,225,080 $ The accompanying notes to the consolidated ?nancial statements are an integral part of these statements. /s/ Mitch Geisler, CEO, Chairman /s/ Rob Landau, CFO, Director November 10, 2025 Leveljump Healthcare Corp. Condensed Consolidated Interim statement of pro?t and loss For the three months and nine months ended September 30, 2025 Stated in Canadian dollars Page | 3 Notes 30-Sep-25 30-Sep-24 30-Sep-25 30-Sep-24 Revenues 4 4,835,912 $ 4,448,956 $ 14,109,748 $ 12,927,183 $ Cost of services 3,437,936 3,261,137 10,044,853 9,253,534 Depreciation and amortization 331,051 418,773 994,368 1,259,304 Other fixed costs 129,420 (108,443) 89,459 121,560 Gross profit 937,504 $ 877,489 $ 2,981,068 $ 2,292,785 $ Administrative expenses 236,487 229,667 781,182 659,685 Depreciation and amortization 49,248 43,103 147,744 98,170 Other operating expenses 387,874 370,768 1,461,741 1,570,076 Operating profit (loss) 263,896 $ 233,951 $ 590,401 $ (35,146) $ Finance costs (224,181) (254,688) (752,704) (762,119) Other income 54,129 15,317 309,342 115,610 Other expense (97,646) - (137,111) (108,162) Profit (Loss) before tax from continuing operations (3,802) $ (5,421) $ 9,927 $ (789,816) $ Deferred income tax recovery - - - - Income tax expense 22,575 - 4,173 - Profit (Loss) for the period (26,378) $ (5,421) $ 5,754 $ (789,816) $ Earnings (Loss) per share Basic, profit (loss) per share 6 (0.000) $ (0.000) $ 0.000 $ (0.008) $ Diluted, profit (loss) per share 6 (0.000) $ (0.000) $ 0.000 $ (0.008) $ Three Months Ended Nine Months Ended The accompanying notes to the consolidated ?nancial statements are an integral part of these statements. Leveljump Healthcare Corp. Condensed Consolidated Interim statement of cash ?ows For the three months and nine months ended September 30, 2025 Stated in Canadian dollars Page | 4 30-Sep-25 30-Sep-24 30-Sep-25 30-Sep-24 O --- perating activities Profit before tax from operations (26,378) $ (5,421) $ 5,754 $ (789,816) $ Profit (loss) before tax from discontinued operations Profit before tax (26,378) $ (5,421) $ 5,754 $ (789,816) $ Adjustments to reconcile profit before tax to net cash flows: Depreciation, plant and equipment and right-of-use assets 357,361 461,975 827,554 1,357,573 Share-based payment expense - 37,100 - 111,300 Recoverty of Statute Barred Liabilities - - (222,327) - Recovery of rent credits - - 299,910 - Equity component of preferred shares 4,268 - 8,998 - Finance costs 187,409 64,320 592,965 192,960 Working capital changes: Decrease (increase) in accounts receivable and prepaid expenses (47,896) 157,426 219,156 240,843 Increase in accounts payable and accrued liabilities 58,209 (198,943) 221,927 392,821 559,351 $ 521,878 $ 1,948,183 $ 2,295,497 $ Interest received Interest paid (123,089) (335,685) (88,334) Net cash flows from (used) in operating activities 409,884 $ 516,457 $ 1,618,253 $ 1,417,347 $ Investing activities Purchase of property, plant and equipment (26,495) (236,471) (435,129) (784,948) Development expenditures - (26,460) Proceeds from sale of investments - - - 1,084,000 ROU Assets - - - (7,167) Purchase of intangible assets - (10,085) - (77,792) Net cash flows from (used) in investing activities (26,495) $ (246,556) $ (461,589) $ 214,093 $ Financing activities Share Capital (8,625) - (17,250) 6,000 Payment of principal portion of lease liabilities (134,945) (100,803) (410,702) (313,572) Repayment of long term debt (204,640) (199,660) (720,558) (538,221) Proceeds from borrowings - - 249,213 - Advances from (to) related party (176,495) (227,457) (253,154) (856,472) Proceeds from preferred shares 18,232 - 54,695 - Net cash flows from (used) in financing activities (506,474) $ (527,920) $ (1,097,756) $ (1,702,265) $ Net increase (decrease) in cash and cash equivalents (123,084) (258,019) 58,908 (70,825) Cash and cash equivalents at beginning of period 234,592 259,441 52,600 72,247 Cash and cash equivalents at end of period 111,508 $ 1,422 $ 111,508 $ 1,422 $ Three Months Ended Nine Months Ended The accompanying notes to the consolidated ?nancial statements are an integral part of these statements. Leveljump Healthcare Corp. Condensed Consolidated Interim statement of cash ?ows For the three months and nine months ended September 30, 2025 Stated in Canadian dollars Page | 5 Reconciliation of changes in liabilities to cash ?ows arising from ?nancing activities, including changes arising from both cash and non-cash items: Loans Preferred shares Lease liabilities Total Balance at December 31, 2024 6,827,899 $ 1,875,222 $ 1,482,322 $ 10,185,443 $ Repayment of long term debt (720,558) - - (720,558) Repayment of interest (335,685) - - (335,685) Proceeds from issuance of long term debt 249,213 - - 249,213 Increases in lease liabilities - - 1,180,900 1,180,900 Repayment of lease liabilities - - (502,584) (502,584) Total changes from financing cash flows (807,030) - 678,315 (128,715) Other changes Interest on bank loans 335,685 - - 335,685 Interest on lease liabilities - - 91,883 91,883 Preferred dividends payable - 541,980 - 541,980 Accretion of preferred shares - 54,694 - 54,694 Total other changes 335,685 596,674 91,883 1,024,242 Balance at September 30, 2025 6,356,554 $ 2,471,896 $ 2,252,520 $ 11,080,970 $ The accompanying notes to the consolidated ?nancial statements are an integral part of these statements. Leveljump Healthcare Corp. C --- ondensed Consolidated Interim statement of changes in equity At September 30, 2025, and 2024 Stated in Canadian dollars except for share amounts Page | 6 Notes Number of common shares Amount Preferred Shares Equity Component Contributed Surplus Deficit Total Equity Balance, December 31, 2023 96,424,729 16,224,025 $ - $ 5,403,863 $ (16,687,685) $ $ 4,940,203 Common shares issued 10 60,000 6,000 - - - 6,000 Share based compensation - - - 148,400 - 148,400 Equity component of preferred shares 10 - - 105,109 - - 105,109 Net profit for the year - - - - 1,160,544 1,160,544 Balance, December 31, 2024 96,484,729 $ 16,230,025 $ 105,109 $ 5,552,263 $ (15,527,141) $ 6,360,256 Equity component of preferred shares - - (17,250) - - (17,250) Net profit for the period - - - - 5,754 5,754 Balance, September 30, 2025 96,484,729 $ 16,230,025 $ 87,859 $ 5,552,263 $ (15,521,387) $ 6,348,759 Balance, December 31, 2022 87,157,229 15,624,067 $ 5,051,321 $ (14,479,568) $ $ 6,195,820 Common shares issued 9,267,500 599,958 - - - 599,958 Issuance of warrants and options - - - 352,542 - 352,542 Net income for the year - - - - (2,208,117) (2,208,117) Balance, December 31, 2023 96,424,729 $ 16,224,025 $ - $ 5,403,863 $ (16,687,685) $ 4,940,203 Common shares issued 60,000 6,000 - - - 6,000 Issuance of warrants and options - - - 111,300 - 111,300 Net loss for the period - - - - (789,816) (789,816) Balance, September 30, 2024 96,484,729 $ 16,230,025 $ - $ 5,515,163 $ (17,477,501) $ 4,267,687 Common Share Capital The accompanying notes to the consolidated ?nancial statements are an integral part of these statements. Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended September 30, 2025 Stated in Canadian dollars except for share amounts Page | 7 1. Corporate information The consolidated ?nancial statements of Leveljump Healthcare Corp. (“Leveljump”) and its subsidiaries (collectively, with Leveljump, the “Company”) for the period ended June 30, 2025, were authorized for issue in accordance with a resolution of the directors on November 10, 2025. Leveljump is a company incorporated and domiciled in Canada and whose shares are publicly traded. The registered office is located at 207-52 Scarsdale Rd., Toronto, ON, M3B 2R7. The Company’s principal business activity is providing radiology services both by providing direct patient images and by providing teleradiology services. Teleradiology is the process of providing remote off site reading of radiology scans such as CT, MRI, US, and X-ray. Hospital staff scan their emergency room patients, then page the Company’s radiologist on call, who can then remotely view, via secured server, the images and diagnose the patient and provide a report back to the hospital. % equity interest Name Principal activities Country of incorporation 2025 2024 Leveljump Healthcare Corp. ("Leveljump") Healthcare management Canada N/A N/A Canadian Teleradiology Services, Inc. ("CTS") Medical imaging Canada 100 100 ADC Imaging Inc. ("ADC") Medical imaging Canada 100 100 Telehospital Canada Inc. ("TLH") Medical services Canada 100 100 The board of directors of the Company have the power to amend these statements after they have been issued. 2. Accounting policies a) Basis of preparation The consolidated ?nancial statements of the Company have been prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB). The co --- ndensed consolidated interim ?nancial statements have been prepared on a historical cost basis. The condensed consolidated interim ?nancial statements are presented in Canadian dollars which is the functional currency of the Company. Going concern These consolidated ?nancial statements have been prepared based on accounting principles applicable to a going concern, which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended September 30, 2025 Stated in Canadian dollars except for share amounts Page | 8 The Company had a loss of $(26,378) for the three months ended September 30, 2025 (September 30, 2024: $(5,421)) and a net income of $5,754 for the nine months ended September 30, 2025 (September 30, 2024: net loss of $(789,816)). As of September 30, 2024, the Company’s accumulated de?cit was $15,521,387 (December 31, 2024: $15,527,141) and a working capital de?ciency of $2,628,513, (December 31, 2024: $(2,967,206)). These conditions indicate that material uncertainties exist that cast signi?cant doubt on the Company’s ability to continue as a going concern. The Company's ability to continue as a going concern is dependent upon its ability to attain pro?table operations and/or to obtain the necessary ?nancing to meet its obligations and repay its liabilities when they come due. The consolidated ?nancial statements do not re?ect adjustments to the carrying values and classi?cation of assets and liabilities that might be necessary should the Company be unable to continue as a going concern, and such adjustments may be material. b) Basis of consolidation The Company has employed the same basis of consolidation as can be found in the Company’s most recent Consolidated Financial Statements as of December 31, 2024. c) Summary of accounting policies The Company has employed the same accounting policies as can be found in the Company’s most recent Consolidated Financial Statements as of December 31, 2024. d) IAS 34 Compliance These Condensed Consolidated Interim Financial Statements comply with IAS 34. 3. Signi?cant accounting judgements, estimates and assumptions The preparation of the consolidated ?nancial statements consistent with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. The preparation of the consolidated ?nancial statements also requires management to exercise judgment in the process of applying the accounting policies. Actual results in the future can differ from these estimates, which may be material to future ?nancial statements. Signi?cant estimates and underlying assumptions are reviewed on a periodic basis. Management uses historical experience and various other factors it believes to be reasonable under the circumstances as the basis for its judgments and estimates. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future period affected. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are signi?cant to the ?nancial statements, are outlined below: Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended Septem --- ber 30, 2025 Stated in Canadian dollars except for share amounts Page | 9 a) Critical accounting estimates The Company has employed the same accounting estimates as can be found in the Company’s most recent Consolidated Financial Statements as of December 31, 2024. b) Critical judgments in applying accounting policies The Company has employed the same critical judgments as can be found in the Company’s most recent Consolidated Financial Statements as of December 31, 2024. 4. Revenues Set out below is the disaggregation of the Company’s revenues: Type of service September 30, 2025 September 30, 2024 September 30, 2025 September 30, 2024 Imaging scans 2,483,854 $ 1,979,578 $ 6,992,087 $ 5,769,110 $ Radiologist fees 2,352,058 $ 2,469,378 $ 7,117,661 $ 7,158,073 $ Total revenue 4,835,912 $ 4,448,956 $ 14,109,748 $ 12,927,183 $ For the three months ended For the nine months ended 5. Operating segments The Company operates as a single segment. All the Company’s core assets, intellectual property, and development work, are conducted in Canada. Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended September 30, 2025 Stated in Canadian dollars except for share amounts Page | 10 6. Earnings/(Loss) per share (EPS) The following table re?ects the income and share data used in the basic and diluted EPS calculations: 30-Sep-25 30-Sep-24 30-Sep-25 30-Sep-24 Profit (Loss) attributable to ordinary equity holders of the parent for basic earnings (26,378) (5,421) 5,754 (789,816) Profit (Loss) attributable to ordinary equity holders of the parent adjusted for the effect of dilution (26,378) $ (5,421) $ 5,754 $ (789,816) $ Weighted average number of ordinary shares for basic EPS 96,484,729 96,484,729 96,484,729 96,484,729 Weighted average number of ordinary shares adjusted for the effect of dilution 96,484,729 96,484,729 96,484,729 96,484,729 30-Sep-25 30-Sep-24 30-Sep-25 30-Sep-24 Profit (Loss) attributable to ordinary equity holders of the parent: Continuing operations (26,378) $ (5,421) $ 5,754 $ (789,816) $ Profit (Loss) attributable to ordinary equity holders of the parent for basic earnings (26,378) (5,421) 5,754 (789,816) Interest on convertible preference shares 128,640 64,320 128,640 64,320 Profit(Loss) attributable to ordinary equity holders of the parent adjusted for the effect of dilution 102,262 $ 58,899 $ 134,394 $ (725,496) $ Weighted average number of ordinary shares for basic EPS 96,484,729 96,484,729 96,484,729 96,484,729 Effects of dilution from: Share options 6,250,000 6,250,000 6,250,000 6,250,000 Share warrants - 7,200,000 - 7,200,000 Convertible preference shares 10,470,000 10,470,000 10,470,000 10,470,000 Weighted average number of ordinary shares adjusted for the effect of dilution 102,734,729 109,934,729 102,734,729 109,934,729 For the three months ended For the nine months ended There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of authorisation of these ?nancial statements. Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended September 30, 2025 Stated in Canadian dollars except for share amounts Page | 11 7. Financial assets and ?nancial liabilities a) Financial assets 30-Sep-25 31-Dec-24 Debt instruments at amortized cost Accounts receivable 1,229,908 1,461,836 Loans receivable from Levelju --- mp Inc. 2,056,908 1,809,362 Total financial assets 3,286,816 $ 3,271,198 $ Total current 1,229,908 $ 1,461,836 $ Total non-current 2,056,908 $ 1,809,362 $ b) Financial liabilities Interest rate Maturity 30-Sep-25 31-Dec-24 Current interest-bearing loans and borrowings, at amortized cost Line of credit Prime + 1.5 On demand 655,309 642,288 Total current interest-bearing loans and borrowings 655,309 $ 642,288 $ Non-current interest-bearing loans and borrowings, at amortized cost Lease liabilities 5.0 - 8.0 2026-2029 2,252,520 1,482,322 $139,735 TD bank loan 6.55 30-Dec-27 68,547 89,247 $172,000 TD bank loan 6.48 11-Jan-28 87,206 112,553 $85,392 TD bank loan 6.28 15-Dec-27 41,747 54,405 $2,912,552 TD bank loan Prime + 1.5 04-Feb-27 2,047,410 2,286,330 $687.669 TD bank loan 6.66 15-Feb-27 547,014 590,526 $203,000 TD bank loan Prime + 1.25 10-Oct-28 125,183 155,633 $3,457,000 TD bank loan Prime + 1.5 10-Oct-28 2,885,477 3,153,926 $120,000 TD bank loan Prime + 1.5 28-Mar-29 85,729 103,729 RB Equipment loan 9.99 01-Apr-29 239,819 281,550 RB Equipment loan 8.99 16-Jul-30 166,914 - Convertible preference shares 12.0 31-Dec-27 1,929,916 1,875,222 Total non-current interest-bearing loans and borrowings 10,477,482 $ 10,185,443 $ Total interest-bearing loans and borrowings 11,132,791 $ 10,827,730 $ Bank loans The Company has various bank loans outstanding, for the purchase of its IHF locations, as well as equipment loans for the purchase of medical equipment. The interest rates on the loans vary from 6.28% to 9.99%. The bank loans are secured by a general security agreement representing a ?rst charge on all the Company's present and future acquired assets. The equipment loan is secured by Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended September 30, 2025 Stated in Canadian dollars except for share amounts Page | 12 medical equipment speci?cally assigned by the Company. The bank loans are amortized over 10 years. The equipment loans are amortized over 5 years. At September 30, 2025, the Company was in compliance with the ?nancial covenants associated with the loans above. Financial covenants The bank loans subject to ?nancial covenants as follows: a) Maintain a Debt Service Coverage ratio (DSC) of not less than 115%. b) Maintain a maximum Funded Debt to Adjusted EBITDA Ratio of 3.00x Operating line of credit The Company has an operating line of credit of $650,000. The Line of Credit is part of the loan facility agreement with the bank and is due on demand, with an interest rate of prime +1.5%, and interest paid monthly. The balance of the line of credit was $651,286 as at September 30, 2025 (December 2024: - $642,288). Preferred shares The preferred shares are classi?ed in the ?nancial tables as non-current liabilities, since they do not meet the equity conditions in IAS 32. See Note 22. c) Other ?nancial liabilities 30-Sep-25 31-Dec-24 Other financial liabilities at amortized cost, other than interest-bearing loans and borrowings Accounts payable 3,665,282 $ 3,441,367 $ Accrued liabilities 83,040 88,700 Preferred dividends payable 541,980 284,700 Income tax payable 2,703 - Total other financial liabilities 4,320,176 $ 3,814,767 $ Total current 3,778,196 $ 3,530,067 $ Total non-current 541,980 $ 284,700 $ Accrued liabilities include Company credit cards and payroll items payable. d) Financial instruments risk management objectives and policies The Company’s principa --- l ?nancial liabilities are comprised of loans and borrowings, and accounts and other payables. The main purpose of these ?nancial liabilities is to ?nance the Company’s operations. The Company’s principal ?nancial assets include accounts receivable, cash that it derives directly from its operations, and loans to related parties. Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended September 30, 2025 Stated in Canadian dollars except for share amounts Page | 13 The Company is exposed to market risk, credit risk and liquidity risk. The Company’s senior management oversees the management of these risks. The Board of Directors reviews and agrees with policies for managing each of these risks, which are summarized below. The sensitivity analyses in the following sections relate to the positions of the Company at September 30, 2025, and December 31, 2024. The sensitivity analysis has been prepared on the basis that the amount of net debt, the ratio of ?xed to ?oating interest rates of debt and derivatives and the proportion of ?nancial instruments in foreign currencies are all constant in place at September 30, 2025. The following assumptions have been made in calculating the sensitivity analysis: The sensitivity of the relevant statement of pro?t or loss item is the effect of the assumed changes in respective risks. This is based on the ?nancial assets and ?nancial liabilities held at September 30, 2025, and December 31, 2024. Market risk Market risk is the risk that future cash ?ows of a ?nancial instrument will ?uctuate because of changes in market prices. Market risk for the Company arises primarily due to interest rate risk. Financial instruments affected by market risk include loans and borrowings, deposits, and debt. Interest rate risk Interest rate risk is the risk that the fair value or future cash ?ows of a ?nancial instrument will ?uctuate because of changes in market interest rates. The Company’s exposure to the risk of changes in market interest rates relates primarily to the Company’s long-term debt obligations with ?oating interest rates. The Company manages its interest rate risk by having a balanced portfolio of ?xed and variable rate loans and borrowings. At September 30, 2025, approximately 34% of the Company’s borrowings are at a ?xed rate of interest (December 31, 2024: 41%). Interest rate sensitivity The following table demonstrates the sensitivity to a reasonably possible change in interest rates on that portion of loans and borrowings affected. With all other variables held constant, the Company’s pro?t before tax is affected through the impact on ?oating rate borrowings, as follows: Increase/decrease in basis points Effect on profit/(loss) before tax 2025 0.50% $ (45,180) 2024 0.50% $ (37,351) The assumed movement in basis points for the interest rate sensitivity analysis is based on the currently observable market environment. Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended September 30, 2025 Stated in Canadian dollars except for share amounts Page | 14 Credit risk Credit risk is the risk that a counterparty will not meet its obligations under a ?nancial instrument or customer contract, leading to a ?nancial loss. The Company is exposed to credit risk from its operating activities (primarily accounts receivables) and from its ?nancing activities, includ --- ing deposits with ?nancial institutions, and loans to related parties. Accounts receivable Customer credit risk is managed by each business unit subject to the Company’s established policy, procedures and control relating to customer credit risk management. At September 30, 2025, the Company had 6 customers (December 31, 2024: 6) that owed it more than $100,000 each and accounted for approximately 75% (December 31, 2024: 75%) of all the receivables outstanding. Almost all the Company’s receivables originate from payments by the governments of Alberta and Ontario. Financial instruments and cash deposits Credit risk from balances with banks and ?nancial institutions is managed in accordance with the Company’s policy. All the Company’s deposits and cash are held at Tier 1 Canadian chartered banks. Loans to related parties The Company has loans to related parties (Note 12) that potentially contain credit risk based on the ability of the borrowers to repay the loans. The Company has reviewed the ?nancial statements of the related party and the assets of the CEO and CFO and has determined that the risk of default on these loans is negligible and thus there is no expectation of credit loss. The Company’s maximum exposure to credit risk for the components of the statement of ?nancial position at September 30, 2025, and December 31, 2024, are the carrying amounts as illustrated in Note 7. Liquidity risk The Company monitors its risk of a shortage of funds through weekly budgeting by management. The Company’s objective is to maintain a balance between continuity of funding and ?exibility using bank lines of credit, bank loans, preference shares, and lease contracts. The Company assessed the concentration of risk with respect to re?nancing its debt and concluded it to be low. The repayment of Company obligations at their carry value is set out in the table below. Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended September 30, 2025 Stated in Canadian dollars except for share amounts Page | 15 September 30, 2025 On demand Less than 3 months 3 to 12 months 1 to 5 years > 5 years Total Interest-bearing loans and borrowings $ 655,309 $ 260,983 $ 782,949 $ 7,123,645 $ - $ 8,822,886 Lease liabilities - 138,743 416,229 1,697,548 - 2,252,520 Convertible preference shares - - - 2,471,896 - 2,471,896 Accounts payable - 3,751,025 - - - 3,751,025 $ 655,309 $ 4,150,751 $ 1,199,178 $ 11,293,089 $ - $17,298,327 December 31, 2024 On demand Less than 3 months 3 to 12 months 1 to 5 years > 5 years Total Interest-bearing loans and borrowings $ 642,288 $ - $ - $ 8,603,153 $ - $ 9,245,441 Lease liabilities - 285,962 793,745 402,615 - 1,482,322 Convertible preference shares - - - 3,132,540 - 3,132,540 Accounts payable and accrued liabilities - 3,530,067 - - - 3,530,067 $ 642,288 $ 3,816,029 $ 793,745 $ 12,138,308 $ - $17,390,370 8. Leases The Company has lease contracts for various imaging centre locations used in its operations. Generally, the Company is restricted from assigning and subleasing the leased assets and some contracts require the Company to maintain certain ?nancial ratios. There are several lease contracts that include extension and termination options and variable lease payments, which are further discussed below. Set out below are the carrying amounts of right-of-use assets recognised and the movements during the period: Cost Office Leases Balance December 31, 2023 2,377 --- ,202 $ Reversal (28,608) Balance December 31, 2024 2,348,594 $ Additions 880,989 Balance September 30, 2025 3,229,583 $ Amortization Balance December 31, 2023 431,772 $ Amortization for the period 502,621 Balance December 31, 2024 934,393 $ Adjustment on lease renewal (141,779) Amortization for the period 7,791 Balance September 30, 2025 1,068,380 $ Net Book Value Balance December 31, 2024 1,414,201 $ Balance September 30, 2025 2,161,202 $ Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended September 30, 2025 Stated in Canadian dollars except for share amounts Page | 16 Set out below are the carrying amounts of lease liabilities (included under interest-bearing loans and borrowings) and the movements during the period: September 30, 2025 December 31, 2024 Beginning of period 1,482,322 $ 1,982,879 $ Additions 1,180,900 - Interest expense 91,883 114,194 Payments (502,584) (614,751) End of period 2,252,520 $ 1,482,322 $ Current 554,972 $ 1,079,707 $ Non-current 1,697,548 $ 402,615 $ 9. Share-based payments 2022 Equity Incentive Plan Under the 2022 Equity Incentive Plan, the Company, at its discretion, may grant share options to any employees, directors or consultants. Vesting of the share options is determined on a case-by- case basis. Generally, employees must remain in service for a period of two years from the date of employment. The fair value of share options granted is estimated at the date of grant using Black- Scholes model, considering the terms and conditions on which the share options were granted. The expense recognised for employee and director services received during the year is shown in the following table: 30-Sep-25 30-Sep-24 30-Sep-25 30-Sep-24 Expense arising from equity-settled share-based payment transactions - $ 37,100 $ - $ 117,300 $ Expense arising from cash-settled share-based payment transactions - - - - Total expense arising from share-based payment transactions - $ 37,100 $ - $ 117,300 $ For the three months ended For the six months ended 10. Issued capital Authorized Share Capital Unlimited number of common shares, with no par value. 10,000,000 Class A-1 Preferred shares with a par value of $1.00 per share. Each Preferred Share is non-voting, carries a cumulative annual dividend of 12% payable quarterly, along with a top up dividend of 25% of the portion of the Company’s EBITDA that is above $2,000,000 per year, divided by the then outstanding Preferred Shares. The Preferred Shares are redeemable on December 31, 2027, (the “Redemption Date”) after issuance at a price of $1.00 per Preferred Share (or at a price of $1.10 per Preferred Share, at the option of the Company, if redeemed any time prior to the Redemption Date) together with all accrued and unpaid dividends. Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended September 30, 2025 Stated in Canadian dollars except for share amounts Page | 17 The Preferred Shares are also convertible at the holder's option, prior to being redeemed or called, into common shares of the Company at a price of $0.20 per Common Share. Subject to applicable law and to certain exceptions, the Company may, at any time prior to the Redemption Date, purchase for cancellation all or any number of the Preferred Shares outstanding from time to time at any price in the open market if they are listed or posted for trading on a s --- tock exchange or by tender available to all of holders of Preferred Shares or by private agreement or otherwise. The preferred shares are classi?ed in the ?nancial tables as non-current liabilities, since they do not meet the equity conditions in IAS 32. The preferred shares were valued at the price of each unit sold, which was $1.00 per unit, with a unit consisting of 1 Class A-1 Preferred Share and 1 Common share. The common shares were valued at the market of $0.10 with the balance of $0.90 of each unit being assigned to the preferred shares less expenses for broker fees. a) Common shares Number of common shares Amount Balance, December 31, 2023 96,424,729 16,224,025 $ Shares issued for employee services (a) 60,000 6,000 Balance, December 31, 2024 96,484,729 16,230,025 $ Balance, September 30, 2025 96,484,729 16,230,025 $ Year Ended December 31, 2024 a) On January 4, 2024, 60,000 shares were issued to a former employee as part of their employment contract. The common shares were valued at $0.10 each. b) Class A-1 Preferred shares Number of preferred shares Amount Balance, December 31, 2023 2,094,000 1,840,500 $ Equity component of preferred shares - (105,109) Accretion of preferred shares - 139,831 Balance, December 31, 2024 2,094,000 1,875,222 $ Accretion of preferred shares - 54,694 $ Balance, September 30, 2025 2,094,000 1,929,916 $ c) Common share options The Company has a 2022 Equity Incentive Plan (the "Plan") under which it is authorized to grant options to purchase common shares of the Company to directors, senior officers, employees and/or consultants of the Company. The aggregate number of shares of the Company which may be issued and sold under the Plan will not exceed 20% of the total number of common shares issued and outstanding as of the date of the RTO transaction. Share options are granted with a maximum term of ten years with vesting requirements at the discretion of the Board of Directors. Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended September 30, 2025 Stated in Canadian dollars except for share amounts Page | 18 The Company records a charge to the statement of loss and comprehensive loss using the Black- Scholes fair valuation option pricing model with respect to a share option grant. The valuation is dependent on several estimates, including the risk-free interest rate, the level of share volatility, together with an estimate of the level of forfeiture. The level of share volatility is calculated with reference to the historic traded daily closing share price at the date of issue. Option pricing models require the input of highly subjective assumptions including the expected price volatility. Changes in the subjective input assumptions can materially affect the fair value estimate, and therefore the existing models do not necessarily provide a reliable measure of the fair value of the Company's share purchase options. Stock Options Number of options Weighted Avg Exercise Price Balance, December 31, 2023 3,600,000 0.20 $ Granted (a) 2,650,000 0.20 Balance, December 31, 2024 6,250,000 0.20 $ Balance, September 30, 2025 6,250,000 0.20 $ a) On January 4, 2024, 2,650,000 options to purchase common stock were issued with an exercise price of $0.20, a term of 3 years, a discount rate of 5.0% and implied volatility of 110%. The value of the options was calculated using a Black-Scholes model. The following table re?ects the actual sto --- ck options issued and outstanding as of September 30, 2025: Exercise price Weighted average Number of Number of Expiry date ($) remaining contractual options options vested life (years) outstanding (exercisable) December 31, 2026 0.20 $ 1.25 2,650,000 2,650,000 December 31, 2025 0.20 $ 0.25 3,600,000 3,600,000 The following table re?ects the actual stock options issued and outstanding as of December 31, 2024: Exercise price Weighted average Number of Number of Expiry date ($) remaining contractual options options vested life (years) outstanding (exercisable) December 31, 2025 0.20 $ 1.00 3,600,000 3,600,000 d) Common share warrants The following table re?ects the continuity of warrants for the period ended September 30, 2024: Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended September 30, 2025 Stated in Canadian dollars except for share amounts Page | 19 Warrants Number of Warrants Weighted Average Exercise Price Balance, December 31, 2023 33,214,927 0.20 $ Expired/Cancelled (26,014,927) 0.20 Balance, December 31, 2024 7,200,000 0.20 $ Expired/Cancelled (7,200,000) 0.20 $ Balance, September 30, 2025 - 0.20 $ There were no warrants outstanding as of September 30, 2025. 11. Commitments and contingencies a) Commitments None. b) Legal contingencies A claim for wrongful dismissal in the amounts of approximately $190,000 was ?led against the Company by a former employee, who is the wife of the previous owner of the ADC Imaging Inc. The Company has cross claimed against the previous owners of ADC for the amounts in question. The Company believes the claim is without merit and plans to defend it vigorously. From time to time the Company is also subject to minor legal claims non of which are anticipated to have any material impact on the Company. 12. Related party disclosures Related parties include key management being the Company's executive officers, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. Purchases from related parties Amounts due from related parties Amounts due to related parties Entity with significant influence over the Company Leveljump Inc. 30-Sep-25 639,923 $ 2,056,908 $ - $ 31-Dec-24 1,695,460 $ 1,809,362 $ - $ Key management personel of the Company 30-Sep-25 - $ - $ 236,677 $ 31-Dec-24 - $ - $ 242,284 $ Purchases from related parties Both the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”) provide their services to the Company through a third-party company Leveljump Inc. that is owned 50% by the CEO and Leveljump Healthcare Corp. Notes to the condensed consolidated interim ?nancial statements For the three months and nine months ended September 30, 2025 Stated in Canadian dollars except for share amounts Page | 20 50% by the CFO. These services are currently billed at $54,807 per month for each officer plus HST. Purchases from related parties are recognized as Other operating expenses in the Consolidated statement of pro?t and loss and as Professional fees in Note 8. The Company also leases its head office location from Leveljump Inc. for $8,000 per month plus HST. The Company has recognized a Right of Use asset of $425,692 for the lease of the head office along with a corresponding Lease Liability of $425,692 for the lease of the head office. Amounts due from related parties These advances are to Leveljump Inc. T --- he loans are unsecured and non-interest bearing and are included in Due from related parties in the Statement of ?nancial position. Amounts due to related parties Past-due salaries to the CEO and CFO are presented in Due from related parties in the Statement of ?nancial position. The loans are unsecured and non-interest bearing and are included in Due from related parties in the Statement of ?nancial position. 13. Events after the reporting period In June 2025, the Company entered an agreement to purchase two new IHF locations in Calgary, AB for $1,972,000 in cash, including a $20,000 deposit already paid by the Company. The transaction is no longer going forward and has been terminated by the Company and the vendor.